Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

Points of interest from Earnings Call:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 110
Posts 24,075
Boards Moderated 14
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/15/2020 7:29:18 AM
Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Modera... Business Wire - 5/15/2020 7:00:00 AM
midastouch017   Tuesday, 06/02/20 04:40:14 AM
Re: midastouch017 post# 1413
Post # of 1449 
Points of interest from Earnings Call:

We had previously announced that we were approved to commence a COVID-19 clinical study in Israel. While we did commence this trial, we have not enrolled patients due to the decreasing number of COVID-19 patients in Israel. We’re now focusing our COVID-19 clinical development in U.S. which currently has the largest number of cases in the world. During the first quarter, we also entered collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia to study the anti-viral activity of Piclidenoson on COVID-19 viral load.



Thank you. Actually, the company now is summarizing all the data and we are participating in the next couple of months in couple of partnering meetings. Yes, we are actively looking at partners and partners -- potential partners are looking at us. And we do hope to partner with this very important clinical indication and be able to accelerate the development.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist